{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:49:16Z","timestamp":1793386156910,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd002309.pub5","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000}}],"reference-count":210,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd002309.pub6","type":"journal-article","created":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T11:28:48Z","timestamp":1588332528000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease"],"prefix":"10.1002","volume":"2020","author":[{"given":"Sadia","family":"Janjua","sequence":"additional","affiliation":[{"name":"Cochrane Airways, Population Health Research Institute; St George's, University of London; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Fortescue","sequence":"additional","affiliation":[{"name":"Cochrane Airways, Population Health Research Institute; St George's, University of London; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillippa","family":"Poole","sequence":"additional","affiliation":[{"name":"Department of Medicine; University of Auckland; Auckland New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,5,1]]},"reference":[{"key":"10.1002\/14651858.CD002309.pub6-BIB0001|cit1","unstructured":"A randomized, 24-week, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety and tolerability of cilomilast (15 mg twice daily) in patients with chronic obstructive pulmonary disease (207499\/039) gsk-clinicalstudyregister.com\/study\/207499\/039#rs"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD002309.pub6-BIB0002|cit2","first-page":"A771","article-title":"Cilomilast (Ariflo), a potent selective phosphodiesterase 4 inhibitor, reduces exacerbations in COPD patients: results of a 6 month trial","volume":"163","author":"Edelson","year":"2001","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD002309.pub6-BIB0003|cit3","first-page":"A277","article-title":"Cilomilast (Ariflo) improves health status in patients with COPD: results of a 6-month trial","volume":"163","author":"Edelson","year":"2001","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD002309.pub6-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1378\/chest.129.1.56","article-title":"Cilomilast for COPD: results of a 6-month, placebo controlled study of a potent, selective inhibitor of phosphodiesterase 4","volume":"129","author":"Rennard","year":"2006","journal-title":"Chest"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0005|cit5","unstructured":"A randomized, 24-week, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety and tolerability of cilomilast (15 mg twice daily) in patients with chronic obstructive pulmonary disease gsk-clinicalstudyregister.com\/study\/207499\/042?search=study&search_terms=cilomilast&search=Search#rs"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0006|cit6","unstructured":"A 12-week, multicentre, double-blind, placebo-controlled, parallel-group study to evaluate the anti-inflammatory activity of SB207499 15 mg twice daily in patients with chronic obstructive pulmonary disease gsk-clinicalstudyregister.com\/files\/pdf\/24047.pdf"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1164\/rccm.200212-1490OC","article-title":"Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease","volume":"168","author":"Gamble","year":"2003","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0008|cit8","unstructured":"A randomized, 24-week, double-blind, placebo-controlled, parallel-group study followed by a 2-week, randomized, double-blind, run-out phase to evaluate the efficacy, safety, tolerability and discontinuation of SB207499 (15 mg twice daily) in patients with chronic obstructive pulmonary disease gsk-clinicalstudyregister.com\/study\/207499\/091?search=study&search_terms=SB207499#rs"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0009|cit9","unstructured":"GSK CTR-657. A randomized, 24-week, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety and tolerability of cilomilast (15 mg BID) in patients with chronic obstructive pulmonary disease (COPD) gsk-studyregister.com\/study?uniqueStudyId=CIL103657"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0010|cit10","unstructured":"A 12-week, multicenter, double-blind, placebo-controlled, parallel-group study to evaluate the anti-inflammatory activity of cilomilast 15 mg twice daily in patients with chronic obstructive pulmonary disease gsk-studyregister.com\/study\/5979"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0011|cit11","unstructured":"A 12-week, randomized, double-blind, placebo-controlled, parallel-group study to investigate the effect of cilomilast (15 mg twice daily) on trapped gas volume in patients with chronic obstructive pulmonary disease gsk-clinicalstudyregister.com\/files\/pdf\/24050.pdf"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD002309.pub6-BIB0012|cit12","first-page":"A226","article-title":"Effect of cilomilast (Ariflo) on trapped gas volume and indices of hyperinflation in patients with chronic obstructive pulmonary disease","volume":"165","author":"Zamel","year":"2002","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0013|cit13","unstructured":"A randomized, 24-week, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety and tolerability of cilomilast (15 mg BID) in patients with chronic obstructive pulmonary disease h\/s3.amazonaws.com\/ctr-gsk-7381\/207499_121\/430f519b-3d76-4244-9417-3bc801497511\/ef158d16-ce04-46dd-8358-456dfee5641f\/24042-v1.pdf"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0014|cit14","unstructured":"A randomized, 24-week, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety and tolerability of cilomilast (15 mg BID) in patients with chronic obstructive pulmonary disease s3.amazonaws.com\/ctr-gsk-7381\/207499_156\/7dd49801-f278-4112-bbe8-f8ef3c62ce78\/f7a0f0ba-f28a-4666-b76a-f155eec89363\/gsk-207499-156-clinical-study-report-redact-v1.pdf"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0015|cit15","unstructured":"A randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety and tolerability of oral cilomilast (15 mg bd) when given as maintenance treatment for 12 months to subjects with chronic obstructive pulmonary disease s3.amazonaws.com\/ctr-gsk-7381\/207499_157\/37e6fc79-d3ca-46e1-b07a-c7c7995d5c69\/31ef48f1-c164-406b-b9db-cf88a0d606dc\/gsk-207499-157-clinical-study-report-redact-v1.pdf"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0016|cit16","unstructured":"A randomized, 12-week, double-blind, placebo-controlled, parallel-group study to evaluate the safety and tolerability of cilomilast 15 mg twice daily in patients with chronic obstructive pulmonary disease gsk-clinicalstudyregister.com\/files\/pdf\/24054.pdf"},{"issue":"Suppl 45","key":"10.1002\/14651858.CD002309.pub6-BIB0017|cit17","first-page":"P522","article-title":"Assessment of cardiac events via 24-hour electrocardiographic (Holter) monitoring with cilomilast in chronic obstructive pulmonary disease","volume":"22","author":"Reisner","year":"2003","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0018|cit18","unstructured":"Reisner C Zhu J Morris A Lim J Knobil K Assessment of cardiac events via 24-hour electrocardiographic (Holter) monitoring with cilomilast in chronic obstructive pulmonary disease American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle 2003"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0019|cit19","unstructured":"An 18-week randomized, double-blind, placebo-controlled, multicenter study designed to compare treatment with cilomilast to that with placebo for changes in ventilatory mechanics and function (both at rest and during exercise), as well as related exertional dyspnea and exercise performance, in hyperinflated patients with stable COPD s3.amazonaws.com\/ctr-gsk-7381\/207499_180\/07613483-8e07-4a60-9f7c-fc673665e770\/b6f75a99-2ac4-4a74-9b06-b5f74ec8c056\/gsk-207499-180-clinical-study-report-redact-v1.pdf"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0020|cit20","unstructured":"A 13-week randomised, double-blind, parallel group, multicentre study to compare the bronchial anti-inflammatory activity of oral cilomilast (15 mg bd) with placebo twice daily in subjects with chronic obstructive pulmonary disease s3.amazonaws.com\/ctr-gsk-7381\/207499_181\/ac461889-1b68-44f0-a3ef-e3f7a9c76c93\/cdcf6d43-b6ec-4d91-a018-d183ceb8b804\/gsk-207499-181-clinical-study-report-redact-v1.pdf"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0021|cit21","unstructured":"Compton CH Gubb J Cedar E Bakst A Nieman RB Amit O SB 207499, a second generation, oral PDE\u2084 inhibitor, improves health status in patients with COPD European Respiratory Society Annual Congress; 1999 Oct 9-13; Madrid 1999 P2237"},{"issue":"9278","key":"10.1002\/14651858.CD002309.pub6-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0140-6736(01)05481-2","article-title":"Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study","volume":"358","author":"Compton","year":"2001","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0023|cit23","unstructured":"Durmowicz AG Cross discipline team leader review, application number 022522Orig1s000 www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/022522Orig1s000CrossR.pdf"},{"issue":"3","key":"10.1002\/14651858.CD002309.pub6-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"184","DOI":"10.22159\/ajpcr.2018.v11i3.21871","article-title":"A clinical study on safety and efficacy of formoterol and tiotropium combination compared to formoterol and tiotropium with roflumilast combination in treatment of moderate to severe chronic obstructive pulmonary disease patients","volume":"11","author":"Kavitha","year":"2018","journal-title":"Asian Journal of Pharmaceutical and Clinical Research"},{"issue":"9","key":"10.1002\/14651858.CD002309.pub6-BIB0025|cit25","first-page":"e9864","article-title":"Effect and safety of roflumilast for chronic obstructive pulmonary disease in Chinese patients","volume":"97","author":"YG","year":"2018","journal-title":"Medicine"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0026|cit26","unstructured":"Pilot study of tetomilast in chronic obstructive pulmonary disease (COPD) associated with emphysema (EMPHASIS) clinicaltrials.gov\/ct2\/show\/NCT00874497"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0027|cit27","unstructured":"A chronic obstructive pulmonary disease (COPD) trial investigating roflumilast on safety and effectiveness in China, Hong Kong and Singapore https:\/\/clinicaltrials.gov\/show\/NCT01313494 2011"},{"issue":"1","key":"10.1002\/14651858.CD002309.pub6-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1378\/chest.13-1252","article-title":"Roflumilast for the treatment of COPD in an Asian population: a randomized, double-blind, parallel-group study","volume":"145","author":"Zheng","year":"2014","journal-title":"Chest"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0029|cit29","unstructured":"A 16-week, randomised, placebo-controlled, double-blind, and parallel group trial to assess the anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease. The ROBERT study clinicaltrialsregister.eu\/ctr-search\/trial\/2011-000582-13\/results"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0030|cit30","unstructured":"Trial to assess the anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease https:\/\/clinicaltrials.gov\/show\/NCT01509677"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0031|cit31","first-page":"A7429","article-title":"Effect of roflumilast on the serum metabolome of COPD patients","volume":"197","author":"Rabe","year":"2018","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S2213-2600(18)30331-X","article-title":"Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial","volume":"6","author":"Rabe","year":"2018","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0033|cit33","first-page":"A7569","article-title":"Reduction in airway eosinophils in patients with COPD treated with roflumilast for 16 weeks: a double-blind, parallel-group, randomised, placebo-controlled biopsy trial","volume":"195","author":"Rabe","year":"2017","journal-title":"American Journal for Respiratory and Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD002309.pub6-BIB0034|cit34","first-page":"375","article-title":"Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol","volume":"7","author":"Calverley","year":"2012","journal-title":"International Journal of COPD"},{"issue":"5","key":"10.1002\/14651858.CD002309.pub6-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.2147\/COPD.S167730","article-title":"Cost-effectiveness of roflumilast as add-on to triple inhaled therapy versus triple inhaled therapy in patients with severe and very severe chronic obstructive pulmonary disease associated with chronic bronchitis in the UK","volume":"13","author":"Kiff","year":"2018","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"issue":"9971","key":"10.1002\/14651858.CD002309.pub6-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(14)62410-7","article-title":"Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial","volume":"385","author":"Martinez","year":"2015","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0037|cit37","unstructured":"Effect of roflumilast on exacerbation rate in patients with COPD treated with fixed combinations of LABA and ICS. A 52-week, randomised double-blind trial with roflumilast 500 \u00b5g versus placebo. The REACT trial clinicaltrials.gov\/show\/NCT01329029"},{"issue":"8","key":"10.1002\/14651858.CD002309.pub6-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1164\/rccm.201503-0543OC","article-title":"A randomized, placebo-controlled trial of roflumilast. Effect on proline-glycine-proline and neutrophilic inflammation in chronic obstructive pulmonary disease","volume":"192","author":"Wells","year":"2015","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD002309.pub6-BIB0039|cit39","first-page":"A3643","article-title":"A randomized, placebo-controlled trial of roflumilast on markers of inflammation in chronic obstructive pulmonary disease (COPD)","volume":"191","author":"Wells","year":"2015","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0040|cit40","unstructured":"Bredenbroker D Syed J Leichtl S Rathgeb F Wurst W Roflumilast, a new, orally active phosphodiesterase 4 inhibitor, is effective in the treatment of chronic obstructive pulmonary disease European Respiratory Society Annual Congress; 2002 14-18 Sep; Stockholm 2002"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD002309.pub6-BIB0041|cit41","first-page":"A595","article-title":"Safety of once-daily roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, in patients with COPD","volume":"165","author":"Bredenbroker","year":"2002","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD002309.pub6-BIB0042|cit42","first-page":"A229","article-title":"Efficacy of once-daily roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, in chronic obstructive pulmonary disease","volume":"165","author":"Leichtl","year":"2002","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0043|cit43","unstructured":"Leichtl S Syed J Bredenbroker D Rathgeb F Wurst W Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, is safe and well tolerated in patients with chronic obstructive pulmonary disease European Respiratory Society Annual Congress; 2002 Sep 14-17; Stockholm 2002"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0044|cit44","unstructured":"Boszormenyi-Nagy G Pieters WR Steffen H Timar M Vinkler I Teichmann P The effect of roflumilast treatment and subsequent withdrawal in patients with COPD American Thoracic Society International Conference; 2005 May 20-25; San Diego 2005"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0045|cit45","unstructured":"Rabe K Similowski T Bredenbr\u00f6ker D Teichmann P B\u00f6sz\u00f6rm\u00e9nyi-Nagy G Onset of action and effect of withdrawal of roflumilast in COPD European Respiratory Society Annual Congress; 2011 Sep 24-28; Amsterdam 2011"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0046|cit46","first-page":"A3773","article-title":"A double blind placebo controlled study to assess the effect of roflumilast in addition to LABA\/LAMA\/ICS treatment in COPD patients using novel biomarkers","volume":"189","author":"De Backer","year":"2014","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"Suppl 58","key":"10.1002\/14651858.CD002309.pub6-BIB0047|cit47","first-page":"4670","article-title":"A double blind placebo controlled study to assess the effect of roflumilast in addition to LABA\/LAMA\/ICS treatment in COPD patients using novel biomarkers","volume":"44","author":"De Backer","year":"2014","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"2","key":"10.1002\/14651858.CD002309.pub6-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1183\/09031936.00011714","article-title":"The effect of roflumilast in addition to LABA\/LAMA\/ICS treatment in COPD patients","volume":"44","author":"De Backer","year":"2014","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0049|cit49","unstructured":"Brown P Clinical pharmacology and biopharmaceutics review(s). Application number 022522Orig1s000 accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/022522Orig1s000ClinPharmR.pdf"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0050|cit50","unstructured":"Brown P Clinical pharmacology and biopharmaceutics review(s). Application number 022522Orig1s000 www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/022522Orig1s000ClinPharmR.pdf"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0051|cit51","unstructured":"Bateman ED Holmes M Muir JF Andrae K Witte S Bredenbroeker D Safety profile of roflumilast, a novel, selective phosphodiesterase 4 inhibitor, in patients with moderate to severe COPD American Thoracic Society 100th International Conference; 2004 May 21-26; Orlando 2004"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0052|cit52","unstructured":"O'Donnell D Muir JF Jenkins C Plit P Brockhaus F Witte S Roflumilast, a novel selective phosphodiesterase 4 inhibitor, improves quality of life and lowers exacerbation rate in patients with moderate to severe COPD [Abstract] American Thoracic Society 100th International Conference; 2004 May 21-26; Orlando"},{"issue":"Suppl 48","key":"10.1002\/14651858.CD002309.pub6-BIB0053|cit53","first-page":"21s","article-title":"Roflumilast an oral once daily PDE4 inhibitor improves lung function and reduces exacerbation rates in patients with COPD","volume":"24","author":"Rabe","year":"2004","journal-title":"European Respiratory Journal"},{"issue":"9485","key":"10.1002\/14651858.CD002309.pub6-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0140-6736(05)67100-0","article-title":"Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial","volume":"36","author":"Rabe","year":"2005","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0055|cit55","unstructured":"Rabe KF Chapman KR Joubert J Vetter N Witte S Bredenboecker D Roflumilast, a novel, selective phosphodiesterase 4 inhibitor, improves lung function in patients with moderate to severe COPD American Thoracic Society 100th International Conference; 2004 May 21-26; Orlando 2004"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD002309.pub6-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"709S","DOI":"10.1378\/chest.126.4_MeetingAbstracts.709S-a","article-title":"Roflumilast improves lung function and quality of life in chronic obstructive pulmonary disease","volume":"126","author":"Rabe","year":"2004","journal-title":"Chest"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0057|cit57","unstructured":"Effect of roflumilast on pulmonary function and respiratory symptoms in patients with chronic obstructive pulmonary disease (COPD) (BY217\/M2-110) clinicaltrials.gov\/ct2\/show\/study\/NCT00062582"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0058|cit58","unstructured":"OPUS study: effect of roflumilast on exacerbation rate in patients with chronic obstructive pulmonary disease (BY217\/M2-111) https:\/\/clinicaltrials.gov\/show\/NCT00076089"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1465-9921-12-18","article-title":"Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD","volume":"12","author":"Rennard","year":"2011","journal-title":"Respiratory Research"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0060|cit60","unstructured":"Rennard SI Calverley PMA Rempel A Bredenbroker D Martinez FJ The effect of roflumilast treatment on exacerbations in patients with COPD results of a pooled analysis of two 1-year studies American Thoracic Society International Conference; 2008 May 16-21; Toronto 2008"},{"issue":"1","key":"10.1002\/14651858.CD002309.pub6-BIB0061|cit61","first-page":"67","article-title":"Efficacy of roflumilast when used with concomitant inhaled corticosteroids from the OPUS\/RATIO studies","volume":"82","author":"Rusch","year":"2011","journal-title":"Respiration"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0062|cit62","doi-asserted-by":"crossref","unstructured":"Rennard SI Calverley PM Goehring UM Bredenbroker D Martinez FJ Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD Respiratory Research 2011 12 18","DOI":"10.1186\/1465-9921-12-18"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0063|cit63","unstructured":"Rennard SI Calverley PMA Rempel A Bredenbroker D Martinez FJ The effect of roflumilast treatment on exacerbations in patients with COPD results of a pooled analysis of two 1-year studies American Thoracic Society International Conference; 2008 May 16-21; Toronto 2008"},{"issue":"1","key":"10.1002\/14651858.CD002309.pub6-BIB0064|cit64","first-page":"67","article-title":"Efficacy of roflumilast when used with concomitant inhaled corticosteroids from the OPUS\/RATIO studies","volume":"82","author":"Rusch","year":"2011","journal-title":"Respiration"},{"issue":"Suppl II","key":"10.1002\/14651858.CD002309.pub6-BIB0065|cit65","first-page":"ii42","article-title":"Effect of roflumilast on lung function and exacerbations in patients with chronic obstructive pulmonary disease: results of a one year study","volume":"2","author":"Calverley","year":"2005","journal-title":"Thorax"},{"issue":"2","key":"10.1002\/14651858.CD002309.pub6-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1164\/rccm.200610-1563OC","article-title":"Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease","volume":"176","author":"Calverley","year":"2007","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0067|cit67","unstructured":"Calverley PM Sanchez-Toril F McIvor RA Teichmann P Bredenbroeker D Fabbri LM Effect of roflumilast on lung function: a 1-year study in patients with severe to very severe COPD Proceedings of the American Thoracic Society; 2006 May 19-24; San Diego 2006"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0068|cit68","unstructured":"Fabbri LM Sanchez-Toril F McIvor RA Teichmann P Bredenbroeker D Calverley PM Effect of roflumilast on exacerbations: a 1-year study in patients with severe to very severe COPD American Thoracic Society Conference; 2006 May 19-24; San Diego 2006"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0069|cit69","unstructured":"Mclvor RA Calverley PM Sanchez-Toril F Teichmann P Bredenbroeker D Fabbri LM Effect of roflumilast on quality of life: a 1-year study in patients with severe to very severe COPD American Thoracic Society Conference; 2006 May 19-24; San Diego 2006 A850"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1465-9921-12-18","article-title":"Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD","volume":"12","author":"Rennard","year":"2011","journal-title":"Respiratory Research"},{"issue":"1","key":"10.1002\/14651858.CD002309.pub6-BIB0071|cit71","first-page":"67","article-title":"Efficacy of roflumilast when used with concomitant inhaled corticosteroids from the OPUS\/RATIO studies","volume":"82","author":"Rusch","year":"2011","journal-title":"Respiration"},{"issue":"Suppl 51","key":"10.1002\/14651858.CD002309.pub6-BIB0072|cit72","first-page":"194s, P1188","article-title":"The 1-year cost effectiveness of roflumilast for the treatment of severe to very severe COPD patients","volume":"30","author":"Rutten-van Molken","year":"2007","journal-title":"European Respiratory Journal"},{"issue":"8","key":"10.1002\/14651858.CD002309.pub6-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2165\/00019053-200725080-00007","article-title":"A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease","volume":"25","author":"Rutten-van Molken","year":"2007","journal-title":"PharmacoEconomics"},{"issue":"5","key":"10.1002\/14651858.CD002309.pub6-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1183\/09031936.00096511","article-title":"Physiological effects of roflumilast at rest and during exercise in COPD","volume":"39","author":"O'Donnell","year":"2012","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0075|cit75","unstructured":"Hui D Mahayiddin A Roa C Kwa KH Bredenbr\u00f6ker D Goehring UM Roflumilast in Asian patients with COPD: a randomised placebo-controlled trial European Respiratory Society Annual Congress; 2011 Sep 24-28; Amsterdam 2011"},{"issue":"4","key":"10.1002\/14651858.CD002309.pub6-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3349\/ymj.2016.57.4.928","article-title":"Efficacy and safety of roflumilast in Korean patients with COPD","volume":"57","author":"Lee","year":"2016","journal-title":"Yonsei Medical Journal"},{"issue":"8","key":"10.1002\/14651858.CD002309.pub6-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1111\/j.1440-1843.2011.02038.x","article-title":"Roflumilast in Asian patients with COPD: a randomized placebo-controlled trial","volume":"16","author":"Lee","year":"2011","journal-title":"Respirology"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0078|cit78","unstructured":"The HERO-study: effects of roflumilast in patients with COPD (Chronic Obstructive Pulmonary Disease) (BY217\/M2-121) clinicaltrials.gov\/ct2\/show\/NCT00108823"},{"issue":"9691","key":"10.1002\/14651858.CD002309.pub6-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(09)61255-1","article-title":"Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials","volume":"374","author":"Calverley","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD002309.pub6-BIB0080|cit80","first-page":"3S","article-title":"Efficacy and safety of the phosphodiesterase-4 inhibitor roflumilast in patients with symptomatic chronic obstructive pulmonary disease in the M2-124 study","volume":"136","author":"Martinez","year":"2009","journal-title":"Chest"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0081|cit81","unstructured":"Effect of roflumilast on exacerbation rate in patients with chronic obstructive pulmonary disease (COPD): the AURA study (BY217\/M2-124) https:\/\/clinicaltrials.gov\/show\/NCT00297102"},{"issue":"4","key":"10.1002\/14651858.CD002309.pub6-BIB0082|cit82","first-page":"119","article-title":"Roflumilast in combination with long-acting bronchodilators","volume":"138","author":"Nowak","year":"2013","journal-title":"Deutsche Medizinische Wochenschrift"},{"issue":"3","key":"10.1002\/14651858.CD002309.pub6-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1183\/09031936.00178710","article-title":"Roflumilast with long-acting beta2-agonists for COPD: influence of exacerbation history","volume":"38","author":"Bateman","year":"2011","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0084|cit84","unstructured":"Calverley P Fabbri L Rabe K Goehring UM Martinez F Efficacy of the PDE4 inhibitor roflumilast in COPD patients with chronic bronchitis European Respiratory Society Annual Congress; 2009 Sep 12-16; Vienna 2009"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0085|cit85","unstructured":"Calverley P Martinez F Goehring UM Bredenbr\u00f6ker D Brose M Vogelmeier C Impact of roflumilast treatment on the rate and duration of exacerbations and overall steroid load in patients with COPD European Respiratory Society Annual Congress; 2011 Sep 24-28; Amsterdam 2011"},{"issue":"9691","key":"10.1002\/14651858.CD002309.pub6-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(09)61255-1","article-title":"Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials","volume":"374","author":"Calverley","year":"2009","journal-title":"Lancet"},{"issue":"9747","key":"10.1002\/14651858.CD002309.pub6-BIB0087|cit87","first-page":"1146","article-title":"Erratum: Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials (The Lancet (2009) 374 (685-694))","volume":"376","author":"Calverley","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD002309.pub6-BIB0088|cit88","first-page":"67","article-title":"Efficacy of roflumilast in patients receiving concomitant treatments for chronic obstructive pulmonary disease over 12 months","volume":"82","author":"Gooss","year":"2011","journal-title":"Respiration"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0089|cit89","first-page":"A4435","article-title":"Efficacy of roflumilast in patients receiving concomitant treatments for chronic obstructive pulmonary disease over 12 months","volume":"181","author":"Hanania","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"2","key":"10.1002\/14651858.CD002309.pub6-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.rmed.2013.09.018","article-title":"Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD","volume":"108","author":"Hanania","year":"2014","journal-title":"Respiratory Medicine"},{"issue":"2","key":"10.1002\/14651858.CD002309.pub6-BIB0091|cit91","first-page":"A13 [50]","article-title":"Efficacy of roflumilast in patients with symptomatic chronic obstructive pulmonary disease (COPD) receiving concomitant bronchodilator treatments","volume":"19","author":"Kaplan","year":"2010","journal-title":"Primary Care Respiratory Journal"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0092|cit92","unstructured":"Martinez F Fabbri L Rabe K Calverley P Safety of the PDE4 inhibitor roflumilast in COPD patients with chronic bronchitis [Abstract] European Respiratory Society Annual Congress; 2009 Sep 12-16; Vienna 2009"},{"issue":"1 MeetingAbstra","key":"10.1002\/14651858.CD002309.pub6-BIB0093|cit93","first-page":"A5373","article-title":"Roflumilast prolongs time to first and subsequent exacerbations in patients with severe to very severe COPD","volume":"183","author":"Martinez","year":"2011","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"1 Meeting Abstr","key":"10.1002\/14651858.CD002309.pub6-BIB0094|cit94","first-page":"A4441","article-title":"Time course and reversibility of weight decrease with roflumilast, a phosphodiesterase 4 inhibitor","volume":"181","author":"Martinez","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD002309.pub6-BIB0095|cit95","first-page":"119","article-title":"Roflumilast in combination with long-acting bronchodilators","volume":"138","author":"Nowak","year":"2013","journal-title":"Deutsche Medizinische Wochenschrift"},{"issue":"5","key":"10.1002\/14651858.CD002309.pub6-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1378\/chest.12-1489","article-title":"Efficacy of roflumilast in the COPD frequent exacerbator phenotype","volume":"143","author":"Wedzicha","year":"2013","journal-title":"Chest"},{"issue":"4","key":"10.1002\/14651858.CD002309.pub6-BIB0097|cit97","first-page":"93S","article-title":"Efficacy and safety of the phosphodiesterase 4 inhibitor roflumilast in patients with symptomatic chronic obstructive pulmonary disease in the M2-125 study","volume":"136","author":"Andrew","year":"2009","journal-title":"Chest"},{"issue":"9691","key":"10.1002\/14651858.CD002309.pub6-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(09)61255-1","article-title":"Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials","volume":"374","author":"Calverley","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD002309.pub6-BIB0099|cit99","first-page":"119","article-title":"Roflumilast in combination with long-acting bronchodilators","volume":"138","author":"Nowak","year":"2013","journal-title":"Deutsche Medizinische Wochenschrift"},{"issue":"4","key":"10.1002\/14651858.CD002309.pub6-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1378\/chest.136.4_MeetingAbstracts.3S-g","article-title":"Additional clinical benefit in patients with chronic obstructive pulmonary disease treated with roflumilast and salmeterol","volume":"136","author":"Chapman","year":"2009","journal-title":"Chest"},{"issue":"2","key":"10.1002\/14651858.CD002309.pub6-BIB0101|cit101","first-page":"A12 [44]","article-title":"Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease (COPD) concomitantly treated with tiotropium or salmeterol","volume":"19","author":"Chapman","year":"2010","journal-title":"Primary Care Respiratory Journal"},{"issue":"9691","key":"10.1002\/14651858.CD002309.pub6-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(09)61252-6","article-title":"Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomised clinical trials","volume":"374","author":"Fabbri","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0103|cit103","unstructured":"Izquierdo JL MacNee W Biermann E McIvor A The PDE4 inhibitor roflumilast provides additional clinical benefit in COPD patients receiving salmeterol European Respiratory Society Annual Congress; 2009 Sep 12-16; Vienna 2009"},{"issue":"4","key":"10.1002\/14651858.CD002309.pub6-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"467A","DOI":"10.1378\/chest.10507","article-title":"Benefit of roflumilast therapy added to salmeterol in patients with varying chronic obstructive pulmonary disease severity","volume":"138","author":"Martinez","year":"2010","journal-title":"Chest"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0105|cit105","unstructured":"Effect of roflumilast on lung function in chronic obstructive pulmonary disease (COPD) patients treated with salmeterol: the EOS study (BY217\/M2-127) https:\/\/clinicaltrials.gov\/show\/NCT00313209"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD002309.pub6-BIB0106|cit106","first-page":"S85","article-title":"Effect of roflumilast treatment on dyspnea in patients with chronic obstructive pulmonary disease","volume":"7","author":"Sun","year":"2012","journal-title":"Journal of Hospital Medicine"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD002309.pub6-BIB0107|cit107","first-page":"S81","article-title":"Effect of roflumilast treatment on health related quality of life in patients with chronic obstructive pulmonary disease","volume":"7","author":"Sun","year":"2012","journal-title":"Journal of Hospital Medicine"},{"issue":"2","key":"10.1002\/14651858.CD002309.pub6-BIB0108|cit108","first-page":"A12 [44]","article-title":"Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease (COPD) concomitantly treated with tiotropium or salmeterol","volume":"19","author":"Chapman","year":"2010","journal-title":"Primary Care Respiratory Journal"},{"issue":"9691","key":"10.1002\/14651858.CD002309.pub6-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(09)61252-6","article-title":"Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomised clinical trials","volume":"374","author":"Fabbri","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0110|cit110","first-page":"S303","article-title":"Roflumilast treatment with concomitant tiotropium: effect on lung function in severe COPD patients","volume":"27","author":"Fabbri","year":"2012","journal-title":"Journal of General Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD002309.pub6-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1378\/chest.136.4_MeetingAbstracts.3S-g","article-title":"Improvements in breathlessness in patients with chronic obstructive pulmonary disease treated with roflumilast and tiotropium","volume":"136","author":"Paggiaro","year":"2009","journal-title":"Chest"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0112|cit112","unstructured":"Rabe K Paggiaro P Bernabeu L Brose M Fabbri L Roflumilast, a PDE4 inhibitor, improves lung function in patients with COPD treated with tiotropium European Respiratory Society Annual Congress; 2009 Sep 12-16; Vienna 2009"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD002309.pub6-BIB0113|cit113","first-page":"A2261","article-title":"Effect of roflumilast treatment added to tiotropium on dyspnea in patients with chronic obstructive pulmonary disease","volume":"185","author":"Rennard","year":"2012","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0114|cit114","first-page":"A4473","article-title":"Effects of roflumilast, a phosphodiesterase 4 inhibitor, on body composition in chronic obstructive pulmonary disease","volume":"181(Meeting Abs","author":"Wouters","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD002309.pub6-BIB0115|cit115","first-page":"A2946","article-title":"Roflumilast treatment in COPD patients taking a fixed-dose combination of long-acting \u03b22 agonist (LABA) and inhaled corticosteroid (ICS): rationale and design of a prospective randomized controlled trial","volume":"185","author":"Ferguson","year":"2012","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0116|cit116","first-page":"OA482","article-title":"Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy","volume":"46","author":"Martinez","year":"2015","journal-title":"European Respiratory Journal"},{"issue":"5","key":"10.1002\/14651858.CD002309.pub6-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1164\/rccm.201607-1349OC","article-title":"Effect of roflumilast and inhaled corticosteroid\/long-acting beta2-agonist on chronic obstructive pulmonary disease exacerbations (RE(2)SPOND). A randomized clinical trial","volume":"194","author":"Martinez","year":"2016","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0118|cit118","unstructured":"A 52-week, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the effect of roflumilast 500 \u00b5g on exacerbation rate in subjects with chronic obstructive pulmonary disease (COPD) treated with a fixed-dose combination of long-acting beta agonist and inhaled corticosteroid (LABA\/ICS) www.who.int\/trialsearch\/Trial2.aspx?TrialID=PER-114-11"},{"issue":"1","key":"10.1002\/14651858.CD002309.pub6-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.2147\/COPD.S109661","article-title":"Effect of roflumilast in COPD patients receiving inhaled corticosteroid\/long-acting beta2-agonist fixed-dose combination: RE2SPOND rationale and study design","volume":"11","author":"Rennard","year":"2016","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD002309.pub6-BIB0120|cit120","first-page":"A5790","article-title":"Effects of roflumilast in COPD patients receiving ICS\/LABA fixed-dose combination: rationale and design of a prospective randomized controlled trial","volume":"191","author":"Rennard","year":"2015","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0121|cit121","first-page":"A1335","article-title":"Effect of roflumilast on cough and sputum in patients with severe or very severe chronic obstructive pulmonary disease (COPD) receiving inhaled combination therapy: evaluation of the exacerbation of chronic pulmonary disease tool-patient reported outcomes (exact-pro) subdomain scores","volume":"195","author":"Sethi","year":"2017","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD002309.pub6-BIB0122|cit122","first-page":"A1484","article-title":"Evaluation of major adverse cardiac events (MACE) in a one-year, placebo-controlled study of roflumilast in patients with chronic obstructive pulmonary disease (COPD): rationale and design","volume":"187","author":"White","year":"2013","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0123|cit123","unstructured":"Urban M Kreibich N Burghuber OC Effects of roflumilast on subclinical atherosclerosis in COPD - a randomised controlled trial clinicaltrialsregister.eu\/ctr-search\/trial\/2011-004152-19\/AT"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0124|cit124","first-page":"PA693","article-title":"Effects of roflumilast on subclinical atherosclerosis in COPD - a randomised controlled trial","volume":"50","author":"Urban","year":"2017","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD002309.pub6-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"170S","DOI":"10.1378\/chest.124.4_MeetingAbstracts.170S-b","article-title":"Effect of cilomilast on quality of life improvement\/deterioration and non-drug costs in patients with chronic obstructive pulmonary disease","volume":"124","author":"Borker","year":"2003","journal-title":"Chest"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0126|cit126","unstructured":"A randomized, open labelled, multi centric parallel group three arms clinical study to evaluate the efficacy and safety of roflumilast 500mcg tablet in chronic obstructive pulmonary disorder who.int\/trialsearch\/Trial2.aspx?TrialID=CTRI\/2012\/09\/002961"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0127|cit127","unstructured":"A clinical trial study of oral Roflumilast 0.5mg Tablet and combination therapy of Roflumilast 0.5 mg tablet plus Salmeterol 25mcg oral inhaler and combination therapy of Roflumilast 0.5 mg tablet plus Tiotropium 9mcg oral inhaler in adult patients with chronic obstructive pulmonary disease who.int\/trialsearch\/Trial2.aspx?TrialID=CTRI\/2014\/01\/004370"},{"issue":"4","key":"10.1002\/14651858.CD002309.pub6-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"171S","DOI":"10.1378\/chest.124.4_MeetingAbstracts.171S","article-title":"Cardiovascular safety of cilomilast in patients with chronic obstructive pulmonary disease","volume":"124","author":"Ferguson","year":"2003","journal-title":"Chest"},{"issue":"4","key":"10.1002\/14651858.CD002309.pub6-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"129S","DOI":"10.1378\/chest.124.4_MeetingAbstracts.129S","article-title":"Effect of cilomilast on chronic obstructive pulmonary disease patients with impaired quality of life","volume":"124","author":"Fischer","year":"2003","journal-title":"Chest"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0130|cit130","first-page":"1:35s","article-title":"First dose bronchodilating effect of phosphodiesterase-4 (PDE-4) inhibition by cilomilast (Ariflo) with or without co-administration of salbutamol and\/or ipratropium in COPD patients","volume":"18(Suppl 33)","author":"Grootendorst","year":"2001","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0131|cit131","first-page":"A226","article-title":"Effect of a PDE4 inhibitor (Bay 19-8004) on FEV1 and airway inflammation in patients with COPD","volume":"165(8 Suppl)","author":"Grootendorst","year":"2002","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"2","key":"10.1002\/14651858.CD002309.pub6-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1094-5539(02)00172-4","article-title":"Does a single dose of the phosphodiesterase 4 inhibitor, cilomilast (15mg), induce bronchodilation in patients with chronic obstructive pulmonary disease?","volume":"16","author":"Grootendorst","year":"2003","journal-title":"Pulmonary Pharmacology and Therapeutics"},{"issue":"12","key":"10.1002\/14651858.CD002309.pub6-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/thx.2006.075937","article-title":"Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD","volume":"62","author":"Grootendorst","year":"2007","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0134|cit134","first-page":"A4444","article-title":"A four-week randomized study of the safety and tolerability of the inhaled PDE4 inhibitor GSK256066 in COPD","volume":"181(Meeting Abs","author":"Lazaar","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0135|cit135","first-page":"A271","article-title":"COPD exacerbation in a 6-month trial of cilomilast (Ariflo), a potent, selective phosphodiesterase 4 inhibitor","volume":"165(Suppl 8)","author":"Kelsen","year":"2002","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0136|cit136","unstructured":"Knobil K Morris A Zhu J Fischer T Reisner C Cilomilast is efficacious in chronic obstructive pulmonary disease American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle 2003 A035; Poster D92"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0137|cit137","first-page":"P530","article-title":"Cilomilast is efficacious in chronic obstructive pulmonary disease","volume":"22(Suppl 45)","author":"Reisner","year":"2003","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0138|cit138","first-page":"88s","article-title":"Cilomilast decreases exacerbations and maintains lung function in patients with poorly reversible COPD","volume":"24(Suppl 48)","author":"Lim","year":"2004","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0139|cit139","unstructured":"Long-term study of safety and efficacy of roflumilast in Japanese patients older than 40 years with chronic obstructive pulmonary disease (APTA-2217-08) clinicaltrials.gov\/show\/nct00246935"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0140|cit140","unstructured":"Roflumilast safety administered once a day on alternate days for two weeks compared to the usual dosage once daily clinicaltrials.gov\/show\/NCT01849341"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0141|cit141","unstructured":"Effects of roflumilast in hospitalized chronic obstructive pulmonary disease (COPD) on mortality and re-hospitalization clinicaltrials.gov\/show\/nct01973998"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0142|cit142","unstructured":"Strategy to improve adherence of roflumilast clinicaltrials.gov\/show\/nct02018432"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0143|cit143","unstructured":"Nieman RB Taneja DT Amit O Benincosa LJ Compton CH Bethala VK The effects of low dose SB207499, a second generation, oral PDE4 inhibitor, in patients with COPD European Respiratory Society Congress; 1999 Oct 9-13; Madrid 1999"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0144|cit144","unstructured":"Pascoe SJ Bonner J Hauffe S Bohnemeier H Gradual dose escalation of QAK423, a novel PDE4 inhibitor, significantly improves the tolerability American Thoracic Society International Conference; 2007 May 18-23; San Francisco 2007"},{"issue":"1","key":"10.1002\/14651858.CD002309.pub6-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"1700158","DOI":"10.1183\/13993003.00158-2017","article-title":"Effect of roflumilast in patients with severe COPD and a history of hospitalisation","volume":"50","author":"Rabe","year":"2017","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1378\/chest.124.4_MeetingAbstracts.127S-c","article-title":"Cilomilast reduces exacerbations in patients with chronic obstructive pulmonary disease","volume":"124","author":"Reisner","year":"2003","journal-title":"Chest"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2165\/0003495-200868002-00002","article-title":"The efficacy and safety of cilomilast in COPD","volume":"68(Suppl 2)","author":"Rennard","year":"2008","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0148|cit148","unstructured":"Brown P Center for drug evaluation and research application number: 022522Orig1s000. Pharmacology review www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/022522Orig1s000PharmR.pdf"},{"issue":"3","key":"10.1002\/14651858.CD002309.pub6-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"425A","DOI":"10.1378\/chest.1834832","article-title":"Analysis of chronic obstructive pulmonary disease exacerbations with the triple therapy compared with dual and single bronchodilator therapy: which treatment is better for patients with severe disease?","volume":"145","author":"Sadigov","year":"2014","journal-title":"Chest"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0150|cit150","first-page":"A3770","article-title":"Analysis of chronic obstructive pulmonary disease exacerbations with the triple therapy compared with dual treatment: is it better treatment tool for patients with severe disease?","volume":"189","author":"Sadigov","year":"2014","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD002309.pub6-BIB0151|cit151","first-page":"A3968","article-title":"Efficacy and safety of dual anti-inflammatory combination of fluticasone and roflumilast for the treatment of COPD: is dual better than single?","volume":"191","author":"Sadigov","year":"2015","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0152|cit152","unstructured":"A multicentre, open-label extension study to evaluate the safety, tolerability and efficacy of oral SB-207499 (15 mg twice daily) in patients with chronic obstructive pulmonary disease www.gsk-clinicalstudyregister.com\/files\/pdf\/24044.pdf"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0153|cit153","unstructured":"A multicenter open-label extension study to evaluate the safety, tolerability and efficacy of oral cilomilast (15 mg twice daily) in patients with chronic obstructive pulmonary disease www.gsk-clinicalstudyregister.com\/files\/pdf\/24045.pdf"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0154|cit154","first-page":"A135","article-title":"Improvement in lung residual volume in patients with COPD roles of anti-inflammation activity of cilomilast","volume":"10(Suppl 3)","author":"Song","year":"2005","journal-title":"Respiratory"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0155|cit155","first-page":"245s","article-title":"The direct costs of exacerbations in COPD and the effect of cilomilast treatment","volume":"20(Suppl 38)","author":"Spencer","year":"2002","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0156|cit156","first-page":"612s [P3598]","article-title":"A 6 week study of the efficacy and safety of UK 500,001 dry powder for inhalation (DPI) in adults with chronic obstructive pulmonary disease","volume":"30(Suppl 51)","author":"Vestbo","year":"2007","journal-title":"European Respiratory Journal"},{"issue":"5","key":"10.1002\/14651858.CD002309.pub6-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1183\/09031936.00068908","article-title":"A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD","volume":"33","author":"Vestbo","year":"2009","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD002309.pub6-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"262S","DOI":"10.1378\/chest.128.4.2551","article-title":"Efficacy and anti-inflammation activity of a selective phospodiesterase-4 inhibitor cilomilast in treatment of COPD","volume":"128","author":"Wang","year":"2005","journal-title":"Chest"},{"issue":"5","key":"10.1002\/14651858.CD002309.pub6-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.pupt.2013.05.004","article-title":"Safety and tolerability of the inhaled phosphodiesterase 4 inhibitor GSK256066 in moderate COPD","volume":"26","author":"Watz","year":"2013","journal-title":"Pulmonary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0160|cit160","unstructured":"Study to evaluate how to optimise the use of roflumilast in subjects who have a lung disease called chronic obstructive pulmonary disease (COPD) clinicaltrialsregister.eu\/ctr-search\/trial\/2013-001788-21\/results"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002309.pub6-BIB0161|cit161","first-page":"S92","article-title":"Pharmacokinetics and pharmacodynamics of a 4-week up-titration regimen of roflumilast in the optimize study OS","volume":"72","author":"Facius","year":"2018","journal-title":"Pneumologie"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0162|cit162","first-page":"A1337","article-title":"Pharmacokinetics of a 4-week up-titration regimen of roflumilast in the optimize study","volume":"195","author":"Bagul","year":"2017","journal-title":"American Journal of Respiratory and Critical Care Medicine."},{"key":"10.1002\/14651858.CD002309.pub6-BIB0163|cit163","unstructured":"Evaluation of tolerability and pharmacokinetics of roflumilast, 250\u03bcg and 500\u03bcg, as add-on to standard COPD treatment to treat severe COPD (OPTIMIZE) clinicaltrials.gov\/ct2\/show\/NCT02165826"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0164|cit164","first-page":"PA308","article-title":"Tolerability of different dosing regimens of roflumilast in severe COPD (OPTIMIZE)","volume":"48","author":"Watz","year":"2016","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2147\/COPD.S154012","article-title":"Use of a 4-week up-titration regimen of roflumilast in patients with severe COPD","volume":"13","author":"Watz","year":"2018","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"issue":"1","key":"10.1002\/14651858.CD002309.pub6-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2466-14-9","article-title":"Implementing lessons learned from previous bronchial biopsy trials in a new randomized controlled COPD biopsy trial with roflumilast","volume":"14","author":"Barnes","year":"2014","journal-title":"BMC Pulmonary Medicine"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0167|cit167","unstructured":"500\u00b5g roflumilast once daily in combination with 50\u00b5g salmeterol twice daily versus 50\u00b5g salmeterol twice daily alone over 52 weeks in patients with COPD who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2004-004442-40-GB"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD002309.pub6-BIB0168|cit168","first-page":"125 [PS160]","article-title":"Placebo controlled study of roflumilast in Bangladeshi COPD patients","volume":"18","author":"Mahmud","year":"2013","journal-title":"Respirology"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0169|cit169","unstructured":"Study to assess efficacy and safety of oglemilast in patients with chronic obstructive pulmonary disease (COPD) clinicaltrials.gov\/show\/NCT00671073"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0170|cit170","unstructured":"Randomized, double-blind, placebo-controlled study to evaluate the effect of roflumilast on endothelial function in patients with chronic obstructive pulmonary disease (REVASC) clinicaltrials.gov\/show\/NCT01595750"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0171|cit171","unstructured":"Impact of roflumilast on visceral adiposity and metabolic profile in chronic obstructive pulmonary disease (RAMBO) clinicaltrials.gov\/show\/NCT01701934"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0172|cit172","unstructured":"Placebo controlled study to assess the effect of Roflumilast in hyperinflated COPD patients in addition to LABA\/LAMA therapy using functional respiratory imaging clinicaltrialsregister.eu\/ctr-search\/trial\/2015-000053-21\/BE"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0173|cit173","unstructured":"Evaluation of the effect of roflumilast in hyperinflated COPD patients using functional respiratory imaging clinicaltrials.gov\/show\/NCT02451540"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0174|cit174","unstructured":"A multicenter randomized double-blind clinical study evaluated the safety, pharmacokinetic and pharmacodynamic characteristics of roflumilast in COPD patients clinicaltrials.gov\/show\/NCT02671942"},{"issue":"6","key":"10.1002\/14651858.CD002309.pub6-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.rmed.2004.11.006","article-title":"COPD, a multicomponent disease: implications for management","volume":"99","author":"Agusti","year":"2005","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1056\/NEJM200007273430407","article-title":"Medical progress: chronic obstructive pulmonary disease","volume":"343","author":"Barnes","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD002309.pub6-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1164\/rccm.200210-1142PP","article-title":"Theophylline: new perspectives for an old drug","volume":"167","author":"Barnes","year":"2003","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD002309.pub6-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1513\/pats.200504-024SR","article-title":"Theophylline in chronic obstructive pulmonary disease: new horizons","volume":"2","author":"Barnes","year":"2005","journal-title":"Proceedings of the American Thoracic Society"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"s252","DOI":"10.1038\/sj.bjp.0706495","article-title":"Phosphodiesterase inhibitors","volume":"147","author":"Boswell-Smith","year":"2006","journal-title":"British Journal of Pharmacology"},{"issue":"8","key":"10.1002\/14651858.CD002309.pub6-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(09)61255-1","article-title":"Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials","volume":"374","author":"Calverley","year":"2009","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD002309.pub6-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1183\/09031936.04.00014304","article-title":"Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS\/ERS position paper","volume":"23","author":"Celli","year":"2004","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0183|cit183","unstructured":"Cochrane Airways Trials Register airways.cochrane.org\/trials-register"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1081\/COPD-200053377","article-title":"Minimal clinically important differences in COPD lung function","volume":"2","author":"Donohue","year":"2005","journal-title":"COPD"},{"issue":"5","key":"10.1002\/14651858.CD002309.pub6-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1067\/mai.2001.119555","article-title":"Cyclic nucleotide phosphodiesterases","volume":"108","author":"Essayan","year":"2001","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"9691","key":"10.1002\/14651858.CD002309.pub6-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(09)61252-6","article-title":"Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomised clinical trials","volume":"374","author":"Fabbri","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0187|cit187","unstructured":"From the global strategy for the diagnosis, management and prevention of COPD, global initiative for chronic obstructive lung disease (GOLD) 2020 goldcopd.org"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0188|cit188","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT 2015"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0191|cit191","doi-asserted-by":"crossref","unstructured":"Higgins JT Savovi\u0107 J Page MJ Elbers RG Sterne AC Chapter 8. Assessing risk of bias in a randomized trial. In: Higgins JT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604.ch8"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1081\/COPD-200050513","article-title":"St. George's Respiratory Questionnaire: MCID","volume":"2","author":"Jones","year":"2005","journal-title":"COPD"},{"issue":"5","key":"10.1002\/14651858.CD002309.pub6-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.chest.2017.10.009","article-title":"Defining the \"frequent exacerbator\" phenotype in COPD","volume":"153","author":"Le Rouzic","year":"2018","journal-title":"Chest Journal"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12931-016-0330-y","article-title":"Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis","volume":"17","author":"Luo","year":"2016","journal-title":"Respiratory Research"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0195|cit195","unstructured":"Mathers C Loncar D Updated projections of global mortality and burden of disease, 2002-2030: data sources, methods and results. Evidence and Information for Policy Working Paper who.int\/healthinfo\/statistics\/bod_projections2030_paper.pdf"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0196|cit196","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed1000097","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement","volume":"7","author":"Moher","journal-title":"PLoS Medicine"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2147\/COPD.S55738","article-title":"Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials","volume":"9","author":"Rennard","year":"2014","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0198|cit198","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"issue":"3","key":"10.1002\/14651858.CD002309.pub6-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s11845-018-1738-9","article-title":"Effect of roflumilast on chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"187","author":"Shen","year":"2018","journal-title":"Irish Journal of Medical Science"},{"issue":"8","key":"10.1002\/14651858.CD002309.pub6-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD002309.pub6-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1164\/ajrccm.157.2.9708012","article-title":"Phosphodiesterase isozymes: molecular targets for novel antiasthma agents","volume":"157","author":"Torphy","year":"1998","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"2","key":"10.1002\/14651858.CD002309.pub6-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1006\/pupt.1999.0181","article-title":"Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic","volume":"12","author":"Torphy","year":"1999","journal-title":"Pulmonary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/S2213-2600(15)00459-2","article-title":"Hyperinflation in COPD exacerbations","volume":"12","author":"Van Geffen","year":"2015","journal-title":"Lancet Respiratory Medicine"},{"issue":"6","key":"10.1002\/14651858.CD002309.pub6-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.rmed.2003.12.012","article-title":"PDE4 inhibitors in COPD - a more selective approach to treatment","volume":"98","author":"Vignola","year":"2004","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0140-6736(07)61382-8","article-title":"COPD exacerbations: defining their cause and prevention","volume":"370","author":"Wedzicha","year":"2007","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2147\/COPD.S89849","article-title":"Roflumilast: a review of its use in the treatment of COPD","volume":"11","author":"Wedzicha","year":"2016","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/thorax.58.1.73","article-title":"Chronic obstructive pulmonary disease. 6: the aetiology of exacerbations of chronic obstructive pulmonary disease","volume":"58","author":"White","year":"2003","journal-title":"Thorax"},{"issue":"3","key":"10.1002\/14651858.CD002309.pub6-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1378\/chest.12-2332","article-title":"Cardiovascular safety in patients receiving roflumilast for the treatment of chronic obstructive pulmonary disease","volume":"144","author":"White","year":"2013","journal-title":"Chest"},{"key":"10.1002\/14651858.CD002309.pub6-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.2147\/COPD.S106370","article-title":"Potential treatment benefits and safety of roflumilast in COPD: a systematic review and meta-analysis","volume":"11","author":"Yuan","year":"2016","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"issue":"11","key":"10.1002\/14651858.CD002309.pub6-BIB0210|cit210","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002309.pub4","article-title":"Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease","author":"Chong","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T10:36:33Z","timestamp":1635503793000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD002309.pub6"}},"subtitle":[],"editor":[{"name":"Cochrane Airways Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":210,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd002309.pub6","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,1]]}}}